Menu

The Future of Dentistry is 3D

stratysThe future of dentistry is here, as Stratasys releases its new 3D printer. The new Objet Eden260VS, which was designed specifically for use in dental and orthodontic offices and labs, takes up roughly the same amount of space as a copier, and is compatible with all Stratasys dental materials, such as VeroDent, VeroDent Plus, and VeroGlaze.

In addition to updating the printer itself, Stratasys has changed VeroGlaze, too. VeroGlaze is used to create veneer try-ins and other precise dental parts. With the recent changes, VeroGlaze now meets the requirements to be considered a Bio-compatible photopolymer, able to withstand standard levels of irritation and mucous-membrane contact of up to 24 hours.

The Objet Eden260VS has been engineered to be easier to use. Changing materials is as simple as inserting a replacement container, and materials are currently available in clear, peach, or beige. With easily-dissolved soluble support materials, users can switch between soluble and water jet settings, eliminating the need to constantly remove the supports manually.

In addition to file management and creating new products for use in the office, the Objet Eden260VS is also optimized for cleaning dental parts with fine features. The entire process of creating models, from scanning to manufacturing, can now be completed in-house. With double the speed of its predecessor, the Objet Eden260V Dental Advantage, the new printer features lower costs per part and higher efficiency.

In a statement, the director of global dental at Stratasys, Avi Cohen, said the following:

“Stratasys is fully committed to the digital dentistry market. The Objet Eden260VS Dental Advantage brings supremely accurate 3D printing technology to any dental lab seeking to benefit from the future of digital dentistry and orthodontics.”

Stratasys is one of the largest firms in the 3D printing industry. With its printers being hailed as incredibly fast and accurate, Stratasys has placed their marketing focus on the medical industry.



Investors Chronicle